Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-12-01

Clinical Trial Update: Soluble CD23 Expression in Asthma Patients Treated With OMA [NA]

View source ↗

Summary

A University of Mississippi Medical Center–sponsored clinical trial evaluating soluble CD23 expression in asthma patients treated with omalizumab was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Omalizumab (Omalizumab)

Snippet

Sponsor: University of Mississippi Medical Center | Conditions: Asthma | NA | Status: TERMINATED